The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
SIP additions at a six-month high amid rising churn
In August, the number of new accounts for systematic investment plans (SIPs) soared to a six-month peak, marking significant activity. Nevertheless, the year-on-year growth showcased